Leukemia

Leukemia is a malignant neoplasm of hematopoietic stem cells or progenitor cells that results in uncontrolled proliferation and accumulation of leukocytes in the bone marrow, peripheral blood, and often other tissues. In veterinary medicine, leukemia is broadly classified into acute and chronic forms based on the cell of origin and clinical progression. Acute leukemias are characterized by the rapid proliferation of immature blast cells (myeloblasts, lymphoblasts, monoblasts) and are typically aggressive, with a short clinical course. Chronic leukemias involve more differentiated cells (small lymphocytes, granulocytes) and have a slower, more indolent progression. Leukemia can be further categorized by the lineage of the neoplastic cells: lymphocytic (lymphoid) or myeloid (granulocytic, monocytic, erythroid, megakaryocytic). The disease is systemic, often involving the bone marrow, peripheral blood, and potentially the spleen, liver, and lymph nodes. In cats, the most common cause is feline leukemia virus (FeLV), while in dogs, leukemia is usually idiopathic or associated with genetic and environmental factors. The clinical presentation varies widely, from asymptomatic incidental findings to severe systemic illness with cytopenias, organ infiltration, and coagulopathies.

The etiology of leukemia in veterinary patients is multifactorial. In cats, the primary causative agent is feline leukemia virus (FeLV), a retrovirus that integrates into the host genome and induces neoplastic transformation of hematopoietic cells. FeLV is transmitted horizontally through saliva, nasal secretions, urine, and feces, and vertically from queen to kittens. Other retroviruses, such as feline sarcoma virus (FeSV), are less commonly implicated. In dogs, no single viral etiology has been confirmed, but genetic predisposition, exposure to ionizing radiation, chemical carcinogens (e.g., benzene, chemotherapeutic agents), and chromosomal abnormalities are suspected. Immune-mediated and chronic inflammatory conditions may also contribute to leukemogenesis. In both species, specific genetic mutations (e.g., in tumor suppressor genes like p53, or oncogenes like c-kit) have been identified in some cases. Additionally, ionizing radiation and certain drugs (e.g., alkylating agents) are known to increase the risk of secondary leukemias.

Leukemia is relatively uncommon in dogs and cats compared to lymphoma. In cats, FeLV-associated leukemia is more prevalent in multi-cat households, outdoor cats, and those with compromised immune systems. The incidence of FeLV has decreased with vaccination and testing, but it remains a significant cause of leukemia in cats. In dogs, acute leukemias (especially acute lymphoblastic leukemia, ALL) are more common than chronic leukemias, and certain breeds such as Golden Retrievers, German Shepherds, and Boxers may have a higher predisposition. Chronic lymphocytic leukemia (CLL) is typically seen in older dogs, with a median age of 10-12 years. There is no strong sex predilection, though some studies suggest a slight male predominance. Geographic variation is minimal, but FeLV is more common in warmer climates where stray cat populations are larger.

Leukemia arises from a single transformed hematopoietic stem cell or progenitor cell that acquires a growth advantage and fails to undergo normal differentiation and apoptosis. This leads to clonal expansion and accumulation of neoplastic cells in the bone marrow, which disrupts normal hematopoiesis, resulting in cytopenias (anemia, thrombocytopenia, neutropenia). The neoplastic cells may then spill into the peripheral blood, leading to leukocytosis. Infiltration of extramedullary tissues, such as the spleen, liver, lymph nodes, and central nervous system, can occur, causing organomegaly and dysfunction. In acute leukemias, the rapid proliferation of blasts leads to a hypercellular marrow, but the cells are often non-functional, leading to bone marrow failure. In chronic leukemias, the cells are more differentiated and may retain some function, but they can still cause cytopenias due to marrow crowding. The release of cytokines and pro-inflammatory mediators can contribute to systemic signs such as fever, weight loss, and cachexia. Coagulopathies may arise from thrombocytopenia, disseminated intravascular coagulation (DIC), or infiltration of the liver.

Predisposing factors for leukemia include retroviral infection (FeLV in cats), genetic susceptibility (certain breeds), exposure to ionizing radiation or chemical carcinogens, prior chemotherapy (especially with alkylating agents), and chronic immune stimulation. Age is a significant factor: acute leukemias are more common in middle-aged to older animals, while chronic leukemias are typically seen in older animals. Immunosuppression, whether due to concurrent infections, stress, or drug therapy, may increase the risk of FeLV infection and subsequent leukemia. In dogs, no specific environmental factors have been definitively identified, but a history of exposure to herbicides or pesticides has been suggested in some epidemiological studies.

Clinical signs of leukemia are variable and depend on the type and stage of the disease. In acute leukemias, signs are often severe and rapidly progressive, including lethargy, anorexia, weight loss, fever, pale mucous membranes (due to anemia), petechiae or ecchymoses (due to thrombocytopenia), and recurrent infections (due to neutropenia). Hepatosplenomegaly and lymphadenopathy may be present. In chronic leukemias, signs may be subtle or absent initially; when present, they include lethargy, decreased appetite, and mild weight loss. Some animals may have no clinical signs and leukemia is discovered incidentally on routine blood work. In FeLV-positive cats, additional signs may include stomatitis, gingivitis, and other FeLV-associated conditions. Neurologic signs can occur if the central nervous system is infiltrated.

Differential diagnoses for leukemia include: 1) Lymphoma (especially stage V with bone marrow involvement) - distinguished by the presence of a solid tumor mass and a more localized distribution; 2) Myelodysplastic syndromes (MDS) - characterized by cytopenias with dysplastic changes in the bone marrow but less than 20% blasts; 3) Severe inflammatory or infectious diseases causing a leukemoid reaction - typically show a left shift with toxic neutrophils and no blast cells; 4) Immune-mediated hemolytic anemia (IMHA) or thrombocytopenia - may cause regenerative anemia and thrombocytopenia but no neoplastic cells; 5) Bone marrow failure syndromes (e.g., aplastic anemia) - present with pancytopenia but no neoplastic infiltration; 6) Multiple myeloma - characterized by monoclonal gammopathy and lytic bone lesions; 7) Systemic histiocytosis or malignant histiocytosis - may present with cytopenias and organ infiltration but histiocytic markers are positive; 8) Ehrlichiosis or other rickettsial diseases - can cause pancytopenia and fever, but serology and PCR are diagnostic; 9) Feline infectious peritonitis (FIP) - may cause fever and organ infiltration, but histopathology and coronavirus serology are helpful; 10) Drug-induced cytopenias - history of drug exposure and resolution upon withdrawal.

The diagnostic approach to leukemia begins with a thorough history and physical examination, with particular attention to mucous membranes, lymph nodes, and abdominal palpation for organomegaly. A complete blood count (CBC) with manual differential and blood smear evaluation is essential. If leukemia is suspected, a bone marrow aspirate and core biopsy are indicated for definitive diagnosis and classification. Flow cytometry and immunophenotyping (e.g., CD3, CD79a for B-cells, CD3 for T-cells, CD14 for monocytes, CD34 for blasts) are recommended to determine the lineage and stage of differentiation. Cytogenetic analysis (e.g., chromosomal abnormalities) and PCR for antigen receptor rearrangements (PARR) can help distinguish reactive from neoplastic proliferations. In cats, FeLV antigen testing (ELISA or IFA) and FeLV PCR are crucial. Additional tests include serum biochemistry, urinalysis, and thoracic and abdominal imaging (radiography, ultrasonography) to assess for organ infiltration and concurrent disease. Coagulation profiles may be indicated if bleeding is present.

Hematology: In acute leukemia, the CBC typically shows severe cytopenias (anemia, thrombocytopenia, neutropenia) and the presence of blast cells in the peripheral blood. The white blood cell count may be normal, decreased, or markedly increased. In chronic leukemia, there is often a marked lymphocytosis (in CLL) or neutrophilia (in chronic myeloid leukemia) with a predominance of mature cells. Anemia is common and may be non-regenerative due to bone marrow infiltration. Serum biochemistry: Common findings include elevated liver enzymes (ALT, ALP) due to hepatic infiltration, hyperbilirubinemia, and azotemia if renal involvement occurs. Hypercalcemia may be seen in some cases of lymphoid leukemia. Hypoalbuminemia and hyperglobulinemia may occur. Urinalysis: May reveal hematuria, proteinuria, or casts if renal infiltration is present. Blood gas analysis: May show metabolic acidosis or respiratory alkalosis depending on systemic status. Specific biomarkers: Elevated lactate dehydrogenase (LDH) and C-reactive protein (CRP) may be seen. In FeLV-positive cats, FeLV antigen is detected in serum. Flow cytometry and immunophenotyping are essential for lineage determination.

Radiography: Thoracic radiographs may reveal sternal lymphadenopathy, pulmonary infiltrates, or pleural effusion. Abdominal radiographs can show hepatosplenomegaly. Ultrasonography: Abdominal ultrasound is useful for assessing liver and spleen size and echotexture, and for detecting abdominal lymphadenopathy. Echocardiography may be indicated if cardiac involvement is suspected. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are advanced imaging modalities that can provide detailed assessment of organ infiltration and central nervous system involvement, but are not routinely performed. Endoscopy is not typically used for leukemia diagnosis.

Bone marrow aspirate cytology is the cornerstone of diagnosis. In acute leukemia, the marrow is hypercellular with a predominance of blast cells (>20% of all nucleated cells). Blasts have a high nuclear-to-cytoplasmic ratio, prominent nucleoli, and fine chromatin. In chronic leukemia, the marrow shows infiltration by mature lymphocytes or granulocytes. Histopathology of bone marrow core biopsy provides architectural details, including cellularity, fibrosis, and infiltration patterns. Special stains, such as myeloperoxidase (MPO) for myeloid lineage, and immunocytochemistry (e.g., CD3, CD79a, CD34) are essential for classification. In cats, FeLV-associated leukemia may show characteristic changes. Extramedullary infiltration in the spleen, liver, or lymph nodes can be confirmed by cytology or histopathology.

Treatment of leukemia depends on the type and stage. For acute leukemias, aggressive chemotherapy is often attempted, but prognosis is poor. Protocols may include induction with vincristine, prednisone, and L-asparaginase, followed by consolidation and maintenance. For chronic lymphocytic leukemia (CLL), treatment is often reserved for symptomatic animals or those with significant cytopenias; chlorambucil and prednisone are commonly used. For chronic myeloid leukemia (CML), hydroxyurea or imatinib may be considered. Supportive care is crucial: fluid therapy, blood transfusions for severe anemia or thrombocytopenia, antibiotics for infections, and antiemetics. In FeLV-positive cats, antiviral therapy (e.g., zidovudine) may be attempted, but efficacy is limited. Nutritional support and management of complications such as hypercalcemia or DIC are essential. In some cases, splenectomy may be considered for massive splenomegaly or immune-mediated cytopenias.

The prognosis for acute leukemia is grave, with median survival times of weeks to a few months despite treatment. Negative prognostic factors include high blast counts, severe cytopenias, and lack of remission. Chronic lymphocytic leukemia has a more favorable prognosis, with median survival times of 1-3 years, especially if treated. Chronic myeloid leukemia may have a variable course. FeLV-positive cats have a poorer prognosis due to the underlying viral infection. Response to initial therapy is a key prognostic indicator; animals achieving complete remission have longer survival.

Follow-up is intensive, especially during chemotherapy. CBCs should be monitored weekly during induction to assess for cytopenias and response. Once remission is achieved, rechecks may be monthly. Bone marrow aspirates may be repeated to confirm remission. Serial monitoring of FeLV status in cats is important. Imaging (ultrasound) may be repeated every 3-6 months to assess organomegaly. Dose adjustments of chemotherapeutic agents are based on hematologic parameters. Long-term management includes monitoring for relapse and managing chronic complications.

Pearls: 1) Always perform a manual blood smear review in any animal with unexplained cytopenias or leukocytosis. 2) Bone marrow evaluation is essential for definitive diagnosis and classification. 3) Flow cytometry is invaluable for distinguishing reactive from neoplastic cells and for lineage determination. 4) In cats, always test for FeLV and FIV. 5) Consider leukemia in any older dog with marked lymphocytosis. Pitfalls: 1) Mistaking a leukemoid reaction for leukemia; look for toxic neutrophils and left shift. 2) Failing to differentiate acute from chronic leukemia, as treatment and prognosis differ. 3) Overlooking concurrent infections or coagulopathies. 4) Using corticosteroids alone in acute leukemia, which may transiently improve signs but delay definitive diagnosis.

For acute lymphoblastic leukemia (ALL) in dogs and cats: Induction: Vincristine 0.5-0.75 mg/m² IV once weekly; L-asparaginase 10,000 IU/m² SC or IM on day 1; Prednisone 2 mg/kg PO q24h, tapering. Cyclophosphamide 200-250 mg/m² IV or PO every 3 weeks. For acute myeloid leukemia (AML): Cytarabine 100 mg/m²/day as a continuous IV infusion for 4 days, or 200 mg/m² IV q12h for 5 days; Doxorubicin 30 mg/m² IV every 3 weeks. For chronic lymphocytic leukemia (CLL): Chlorambucil 0.2 mg/kg PO q24h for 1-2 weeks, then 0.1 mg/kg q48h; Prednisone 1-2 mg/kg PO q24h, tapering. For chronic myeloid leukemia (CML): Hydroxyurea 50 mg/kg PO q24h, adjusted to maintain WBC <50,000/µL. Supportive care: Maropitant 1 mg/kg IV or PO q24h for nausea; Ondansetron 0.5-1 mg/kg IV q12h; Filgrastim (recombinant human G-CSF) 5 µg/kg SC q24h for neutropenia (use cautiously, may not be effective in all species); Blood transfusions as needed. Antibiotics: Amoxicillin-clavulanate 13.75 mg/kg PO q12h for infections. All dosages should be adjusted based on renal and hepatic function and hematologic monitoring.

Veterinary literature on leukemia is limited compared to lymphoma. Key studies include: 1) A retrospective study by Vail et al. (1996) on acute leukemia in dogs, reporting a median survival of 19 days with treatment. 2) A study by Novacco et al. (2016) on FeLV-associated leukemia in cats, highlighting the importance of FeLV vaccination and testing. 3) A consensus statement from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and treatment of lymphoma and leukemia in dogs and cats (2016) provides guidelines for chemotherapy protocols. 4) A study by Comazzi et al. (2011) on flow cytometric immunophenotyping in canine chronic lymphocytic leukemia, demonstrating the utility of CD21 and CD5 markers. 5) A meta-analysis by Ito et al. (2013) on the use of L-asparaginase in canine acute lymphoblastic leukemia, showing a response rate of 30-50%. 6) The ACVIM consensus on the management of FeLV infection (2020) recommends antiviral therapy and supportive care. Overall, evidence is largely retrospective, and prospective randomized trials are needed to optimize treatment protocols.